J. Safra Sarasin Holding AG Buys Shares of 12,436 Vaxcyte, Inc. (NASDAQ:PCVX)

Key Points

• J. Safra Sarasin Holding AG has purchased a new stake in Vaxcyte, acquiring 12,436 shares valued at approximately $470,000.
• Vaxcyte has received numerous upgrades, with analysts issuing a consensus rating of "Buy" and a price target of $136.50.
• Vaxcyte currently has a market capitalization of $4.35 billion and reported a loss of ($1.04) earnings per share for the last quarter.

J. Safra Sarasin Holding AG purchased a new position in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 12,436 shares of the company's stock, valued at approximately $470,000.

Other institutional investors and hedge funds have also modified their holdings of the company. National Bank of Canada FI acquired a new position in Vaxcyte in the 4th quarter valued at $41,000. Parallel Advisors LLC increased its stake in shares of Vaxcyte by 203.6% during the 1st quarter. Parallel Advisors LLC now owns 1,597 shares of the company's stock valued at $61,000 after acquiring an additional 1,071 shares during the last quarter. IFP Advisors Inc increased its stake in shares of Vaxcyte by 376.4% during the 1st quarter. IFP Advisors Inc now owns 1,653 shares of the company's stock valued at $62,000 after acquiring an additional 1,306 shares during the last quarter. GF Fund Management CO. LTD. purchased a new position in shares of Vaxcyte during the 4th quarter worth about $214,000. Finally, Nisa Investment Advisors LLC increased its position in Vaxcyte by 10.9% during the first quarter. Nisa Investment Advisors LLC now owns 2,977 shares of the company's stock worth $112,000 after purchasing an additional 293 shares during the last quarter. Institutional investors and hedge funds own 96.78% of the company's stock.

Vaxcyte Trading Down 1.1%

PCVX traded down $0.33 on Friday, reaching $29.68. The company had a trading volume of 1,320,902 shares, compared to its average volume of 1,783,931. The company has a market capitalization of $3.83 billion, a P/E ratio of -7.23 and a beta of 1.21. The company has a fifty day moving average of $34.48 and a 200-day moving average of $49.08. Vaxcyte, Inc. has a one year low of $27.66 and a one year high of $121.06.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last announced its earnings results on Wednesday, August 6th. The company reported ($1.22) EPS for the quarter, missing the consensus estimate of ($1.12) by ($0.10). During the same period in the previous year, the company earned ($1.10) earnings per share. Research analysts predict that Vaxcyte, Inc. will post -4.21 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on PCVX shares. Cowen reiterated a "buy" rating on shares of Vaxcyte in a research note on Thursday. Cantor Fitzgerald started coverage on Vaxcyte in a report on Tuesday, April 22nd. They issued an "overweight" rating for the company. Ten research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Vaxcyte presently has a consensus rating of "Buy" and an average target price of $136.50.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.